Author: Tom Wilemon
Gift in memory of Phran Galante boosts lung cancer research
Feb. 25, 2021—A gift in memory of music industry executive and community philanthropist Phran Galante will support the work of Christine Lovly, MD, PhD, associate professor of Medicine and Ingram Professor of Cancer Research, to improve targeted therapies for lung cancer.
Convalescent plasma improved survival in COVID-19 patients with blood cancers
Feb. 5, 2021—Treatment with convalescent plasma vastly improved the survival rate of patients hospitalized for COVID-19 who also had hematologic malignances that compromise the immune system, according to new data released by the COVID-19 and Cancer Consortium (CCC19).
Process ensures follow-up of incidental radiology findings
Feb. 4, 2021—When people go to an emergency room after being injured, suspicious images may show up on their imaging scans that are unrelated to their injuries but may be indicative of cancer. A team at Vanderbilt University Medical Center recently established a better process for ensuring these patients receive follow-up diagnostic care, an initiative that is already receiving national recognition.
Study shows healthy diet is associated with diverse and health-promoting microbiome
Jan. 27, 2021—Scientists are just beginning to understand the impact of diet on the gut microbiome and how this interaction affects human health, but baselines must first be established to yield answers.
Peal named Cancer Center associate operating officer
Jan. 21, 2021—Karline Peal, MBA, BS, AS, RTT, was recently named associate operating officer of Vanderbilt-Ingram Cancer Center (VICC).
Pal named to cancer research national leadership posts
Dec. 28, 2020—Tuya Pal, MD, Ingram Professor of Cancer Research and associate director for Cancer Health Disparities at Vanderbilt-Ingram Cancer Center, has been named to two cancer research leadership posts.
Arthritis drug may treat immunotherapy-related heart complication
Dec. 22, 2020—by Tom Wilemon A drug typically prescribed for rheumatoid arthritis may also be effective in treating a rare but potentially deadly heart complication some cancer patients experience after taking immunotherapies, according to a study published in Cancer Discovery and co-led by investigators at Vanderbilt University Medical Center. The researchers demonstrated that the drug abatacept reduced...
Study reveals distinct genomic landscape for young adults with appendiceal cancer
Dec. 17, 2020—The first study to compare molecular landscapes of early-onset and late-onset appendiceal cancer has revealed distinct non-silent mutations in the tumors of younger patients, setting the stage for the development of potential therapeutic advances for this rare disease.
NCI director urges action to address delayed cancer diagnoses
Nov. 23, 2020—Delayed cancer diagnoses and treatment due to concerns about potential coronavirus exposure will lead to collateral deaths beyond the pandemic, National Cancer Institute (NCI) Director Ned Sharpless, MD, said Thursday during a virtual visit at Vanderbilt University Medical Center.
Hot spots identified for colorectal cancer mortality rates among young women
Nov. 23, 2020—Women diagnosed with early-onset colorectal cancer have a greater risk of dying from the disease depending upon their county of residence, according to a study published in Clinical and Translational Gastroenterology.
New drug for metastatic colorectal cancer enters phase 3 trial
Nov. 18, 2020—A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration is being tested in a phase 3 clinical trial at Vanderbilt-Ingram Cancer Center.
Study underscores importance of personalized medicine in kidney cancer
Nov. 10, 2020—A new study sheds light on how molecular subsets within the tumors of kidney cancer patients determine treatment outcomes and underscores the importance of personalized medicine in making therapy decisions.
